Title of article
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Author/Authors
André J. Scheen، نويسنده , , Nick Finer، نويسنده , , Priscilla Hollander، نويسنده , , Michael D Jensen، نويسنده , , Luc F Van Gaal and for the STORM Study Group، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2007
Pages
13
From page
1660
To page
1672
Abstract
Background
Rimonabant, a selective cannabinoid type 1 receptor blocker, reduces bodyweight and improves cardiovascular and metabolic risk factors in non-diabetic overweight or obese patients. The aim of the RIO-Diabetes trial was to assess the efficacy an
Journal title
The Lancet
Serial Year
2007
Journal title
The Lancet
Record number
590508
Link To Document